Effect of Exercise on Bone Mineral Density, Walking balance, Muscle Strength and Quality of Life in Adults with Diabetic Neuropathy

Therapeutic Exercise as a Modulator of Bone Remodeling, Inflammatory Pathways, and Neuromuscular Performance in Adults with Diabetic Neuropathy: A Randomized Controlled Mechanistic Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202602769735505

Enrollment

130

Registered

2026-02-10

Start date

2025-10-31

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Injury, Occupational Diseases, Poisoning Musculoskeletal Diseases

Interventions

Balance and functional training

Resistance training

Aerobic training

Control Group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants will be eligible for inclusion if they meet all the following conditions: Adults aged 40–70 years. Clinically confirmed type 2 diabetes mellitus (diagnosed =1 year). Diagnosed with diabetic peripheral neuropathy (DPN), confirmed by clinical assessment (e.g., vibration perception threshold, monofilament testing, or neuropathy symptom score). Medically stable and cleared for moderate exercise by a physician. Able and willing to participate in a 12–24 week supervised exercise program. Provide written informed consent to participate.

Exclusion criteria

Exclusion criteria: Participants will be excluded if any of the following apply: Presence of severe cardiovascular disease (e.g., unstable angina, recent myocardial infarction, uncontrolled hypertension). Advanced renal disease (e.g., chronic kidney disease stage =4) or hepatic failure. Severe musculoskeletal or orthopedic conditions limiting mobility or exercise participation. Active foot ulcers, amputations, or severe deformities that impair ambulation. Severe visual impairment or vestibular disorders affecting balance. Neurological or psychiatric disorders unrelated to diabetes that affect motor or cognitive function (e.g., stroke, Parkinson’s disease). Current participation in another structured exercise or clinical trial. Pregnancy or planning to become pregnant during the study period. Non-adherence risk, such as inability to attend regular supervised sessions or cognitive impairment precluding informed consent.

Design outcomes

Primary

Measure	Time frame
Change in bone metabolism biomarkers (BALP, pyridinoline) Change in inflammatory markers (IL-6, TNF-a, CRP, IL-10) Change in neuromuscular performance (grip strength, knee strength, TUG, SPPB, BBS, single-leg stance, 6MWT, nerve conduction velocity)	—

Secondary

Measure	Time frame
Bone Mineral Density (BMD via DXA) Quality of life (SF-36, WHOQOL-BREF) Functional independence indices	—

Countries

Nigeria

Contacts

Public ContactEkundayo Fatai

Physiotherapist

fataidayo.fd@gmail.com09031747608

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026